Natural products often contain scaffolds or core structures that prevent immediate synthetic accessibility. It is, therefore, desirable to find isosteric chemotypes that allow for scaffold-hopping or re-scaffolding. The idea is to obtain simpler chemotypes that are synthetically feasible and exhibit either the same or similar bioactivity as the original natural product or reference compound. We developed and applied a virtual screening technique that represents a molecular scaffold by its side-chain attachment points (exit-vectors) and properties of the side-chain substituents. The technique was validated by retrospective screening for beta-turn mimetics and HMG-CoA inhibitors. A prospective application aimed at finding new chemotypes of PPAR-alpha agonists. Two such compounds were found in a commercially available screening compound library yielding EC 50 values in the low micromolar range. This study demonstrates the applicability of exit-vector based virtual screening to scaffold-hopping tasks.
Medicinal chemistry is usually performed via chemotype-specific compound libraries that can be rationally designed to contain a desired degree of diversity [1] . However, seeking for diverse molecular frameworks in a particular project is desirable, because different chemotypes offer opportunities in terms of chemical accessibility and prospects for lead optimization. Finding new leads via bioisosteric replacement aims at "compounds or groups that possess near-equal molecular shapes and volumes [1] and affect the same biochemically associated systems" [2] . The term "scaffold-hopping" has been introduced to highlight a particular aspect of bioisosteric replacement, namely the "identification of (partially) isofunctional molecules with a different backbone or scaffold architecture" [3] . Scaffoldhopping can also be applied to move from complex natural substrates to more simplistic and synthetically more easily accessible drug-like agents. The identification of potential scaffold-hops is almost always grounded on molecular similarity: one intends to deduce functional similarity in the limit of structural similarity. Ideal screening methods that perform successful scaffold-hops would not only find a maximum number, but also a maximally diverse set of chemotypes from a given chemical subspace. In a way, this seemingly contradicts the similarity principle stating that similar compounds should exhibit a similar function or property [4] . It is apparent however, that functional similarity does not necessarily require structural similarity of isofunctional ligands at the atomic level. An appropriate level of abstraction from the atomistic molecular representation is required to consider different chemotypes as functionally similar.
One starting point for moving from natural products to synthetically tractable molecules is to keep the functional groups or pharmacophoric points fixed and select for alternative connecting core structures. This process of "re-scaffolding" can be automated using virtual screening methodology. Several such software solutions have been devised recently [5] . Here we present our approach to solving the problem of rescaffolding together with a validation study and an experimental confirmation of its applicability.
Virtual screening method:
For virtual screening of compound databases, we analyzed molecules for their scaffold architecture and side-chain properties. Relative side-chain orientations were defined as pairs of exit-vectors ( Figure 1 ). Originally, this idea had been introduced by Lauri and Bartlett in the CAVEAT implementation [6] . The molecular scaffold is defined as the largest connected ring system, and an "extended scaffold" contains connected ring systems that are separated by exactly one bond length ( Figure 1a ). Acyclic molecules do not contain a scaffold according to this definition and are therefore not processed. The position of an exitvector is defined by the base atom, which belongs to the scaffold (b i ), and the orientation through the bond from the base atom to the adjacent atom of the sidechain (t i ) ( Figure 1b ). A set of such vector pairs determines the relationship between the exit-vectors in three-dimensional space. Each vector pair was described by four attributes (Figure 2 ):
Properties and pharmacophoric features of the sidechains were stored together with the vector pair parameters. These features were encoded as a topological R-group descriptor following the concept of Willett and coworkers [7] . The R-group descriptor characterizes the pharmacophoric features at different topological positions from the attachment-point t of the side-chain. For example, Figure 3 shows the Rgroup descriptor for a side-chain considering three properties. To enable the comparison of vector pairs with side-chains of different size the remaining positions of the smaller substituent were zero-filled. For the current analysis, substituents were described using eight atomic properties: atomic weight; atomic positive and negative charge [8] ; hydrogen-bond donor count; hydrogen bond acceptor count; van der The scaffold from which the exit vectors to the functional groups come off is defined as either the largest directly connected ring system or the largest connected rings system, where single rings can also be separated by exactly one bond length. b) The orientation of side-chains are given by their base atoms b on the molecular scaffold, and the adjacent atoms on the side-chain ("tip atoms", t). In the case of a scaffold with three sidechains, three exit-vectors (r1, r2, r3) can be defined. Waals radii, hydrophobicity (xlogP) [9], and topological polar surface area (PSA) [10] . For the sake of similarity searching, all values were scaled to the interval [0,1].
In addition to the R-group descriptor, a description of molecular shape was included. In preliminary experiments, we found this feature useful for the distinction of molecules which have a similar scaffold but very different substitution patterns, for molecules with large side-chains or with vector pairs on just one side of the scaffold. Therefore, the three principle components (PC) were calculated from the atomic coordinate matrix, and the Eigenvalues stored together with the exit-vector pairs. Similarity between two molecules was computed as the Tanimoto coefficient between their vector representations containing information about the exitvector pairs, the R-group descriptor, and the PCA shape descriptor. A query molecule consists of at least two exit-vectors. Optional pharmacophoric features of the side-chain and/or the dimension of the molecules may be considered for virtual screening purposes. Tolerance ranges for the geometric parameters of the query molecules can be used to find "similar" vector pairs.
Both the generation of the reference database and the retrieval of possible hits in the reference database were implemented in Java (Sun Microsystems, Inc; http://java.sun.com). The "Chemistry Development Kit" (CDK) [11] was embedded as the cheminformatics library. Import and export of SD files [12] , basic functionalities for structure handling, as well as the pharmacophore descriptors, were provided by CDK. Prior to similarity searching, screening compound databases were filtered to remove counter ions, bases were protonated, acids de-protonated, and duplicate structures were removed using MOE (Chemical Computing Group, Montreal, Canada). Three-dimensional molecule conformations were generated using CORINA (Molecular Networks, Erlangen, Germany), with driver options "r2d,rc,mc=10,flapn,sc".
Beta-turn mimetics:
In a preliminary experiment, we aimed at finding beta-turn mimetics. A beta-turn was randomly selected from a protein structure, a decarboxylase that was resolved by X-ray crystallography at a high resolution (third beta-turn from PDB entry 2hbv, 1.7 Å resolution) [13] . A type-I beta turn contains four amino acid residues with a stabilizing hydrogen bridge between backbone atoms of residues X 1 and X 3 (Figure 4 ). Since beta-turns are often located at the surface of proteins and represent relatively rigid structures, beta-turn bioisosters have been in the focus of pharmaceutical drug design for a long time. For example, researchers from Ono Pharmaceuticals succeeded in the design of spirodiketopiperazine-based beta-turn mimetics that act as potent chemokine receptor CCR5 antagonists resulting in a reduction of HIV infectivity in cellular assays [14] . Spirodiketopiperazines are also known to bind to other GPCR targets, for example to the neurokinin, melanocortin, and serotonin receptor. Apparently, there exist certain spatial patterns of interaction points that interact favorably with a variety of proteins. This and similar observations provide a basis for the rational design of small molecular weight ligands. It is possible that the "universe" of bioactive ligands reflects in some way the structures and "biophoric patterns" presented by their macromolecular receptors. Figure 5 shows two scaffolds that are considered similar to the beta-turn reference conformation. It is apparent that both the orientation of the three exitvectors X 1 , X 2 , and X 3 , as well as the overall shape of the structures are similar. This example demonstrates that bioisosteric matching of a natural template (betaturn) and synthetic small molecular scaffolds is possible. The type-I beta-turn template structure (PDB entry: 2hbv, third beta-turn) and the matching scaffolds are shown. Side-chains are indicated by X1, X2, and X3.
Scaffold-hopping between statins. The natural
product Compactin from fungal sources served as the query structure in a second virtual screening study. Compactin (Mevastatin) and its derivatives (type 1 statins) are competitive inhibitors of HMG-CoA (3-hydroxy-3-methyl-glutaryl) reductase, which catalyzes the conversion of HMG to mevalonic acid as the rate limiting step of cholesterol biosynthesis [15] . Statins are effective cholesterol lowering compounds in humans. While type 1 statins (Compactin, Lovastatin, Pravastatin, Simvastatin) feature a decalin ring linked to the HMG-like moiety and a butyryl group, type 2 statins (Fluvastatin, Cerivastatin, Atorvastatin, Rosuvastatin) are synthetic inhibitors containing an N-substituted heteroaromatic scaffold (e.g. pyrrol) with characteristic fluorophenyl and methylethyl sidechains [15] . Due to the different scaffold volumes, we were not able to substitute the type 1 with the type 2 scaffold based on the automatically generated exitvector descriptor. Therefore, we manually extended the Compactin query: The butyryl group of type 1 statins occupies a similar region as the fluorophenyl group of type 2 statins, and superposition of Compactin (type 1 statin) and Atorvastatin (type 2 statin) suggests the methyl group of the α-methylbutyrate portion as a third exit vector ( Figure 6 ), possibly enabling a scaffold-hop from type 1 to type 2 statins.
By applying this extended exit-vector descriptor to Compactin (three exit-vector query, Figure 6 ), we virtually screened the COBRA collection of pharmacologically active compounds (version 6.1, 7,589 unique molecules [16] ). HMG-CoA inhibitors were contained in this screening compound set. Additionally, nine HMG-CoA inhibitors from PDB Structures were added to the screening library. In total, it contained seven type 1 statins, 12 type 2 statins and 12 other HMG-CoA ligands. A co-crystal structure of Compactin served as the reference conformation (PDB identifier: 1hw8). For the COBRA compounds, up to 100 conformers were generated using the heuristic conformer generator CORINA (Molecular Networks, Erlangen, Germany). Angular tolerance was set to 65º, and distance tolerance was 0.5 Å. As a result of virtual screening, all of the 12 type 2 statins and two additional HMG-CoA ligands were found among the 42 top-ranking compounds. It is noteworthy that among the top 42 compounds, several tachykinin (NK1, NK2) antagonists were retrieved. It is known that statins induce myopathy [17] , and based on our results it might be worthwhile testing statins for tachykininrelated effects like fibromyalgia [18] .
This outcome confirms the re-scaffolding capability of our exit-vector approach, but also recommends visual inspection and some manual modification of queries to obtain meaningful results. [15] ) and type 2 (Atorvastatin, PDB identifier: 1hwk, 2.2 Å resolution [24] ) statins. Enzyme-bound conformations of the two reference molecules were superimposed, and a Compactin-based query with three exit vectors was formulated. This representation allowed for scaffold-hopping between type 1 and type 2 statins in a virtual screening experiment.
Prospective screening: PPARα α α α agonists. Motivated by the preliminary retrospective virtual screening studies we used the exit-vector approach in prospective setting. The aim was to find novel activators of peroxisome proliferator-activated receptor alpha (PPARα). PPARs are pharmaceutically relevant members of the nuclear receptor superfamily [19] . Although agonists of PPARα and PPARγ subtypes have been approved for treatment of dyslipidemia and type-2 diabetes, safer and receptor subtype-selective lead structures are required [20] . The two reference compounds 1 and 2 are known potent PPARα agonists (Figure 7) [21]. They possess the characteristic fibrate head group interacting with the AF2 "activation" helix of the receptor [22] .
Three-dimensional conformations of the reference compounds were generated by CORINA (one for molecule 1, 10 for molecule 2) and energyminimized within MOE (vide supra). The SPECS catalogue of screening substances was used for candidate retrieval (199,272 compounds, version 06.2007; www.specs.net). Angular tolerance was set to 15º, and distance tolerance was 0.5 Å. The output was limited to structures with exit-vector and R-group similarity > 0.6, and PCA shape descriptor similarity > 0.8. As a result, compound 1 led to 3,740 matches, and compound 2 yielded 5,177 virtual hits. Then, we eliminated all virtual hits that did not contain an acid function, which shortened the virtual hit lists to 142 and 188 compounds, respectively. Manual inspection of the top-ranking SPECS compounds resulted in a final list of seven substances that were ordered and tested for PPARα activation in a cell-based reporter gene assay [23] .
Two new bioactive compounds were identified: Molecules 3 (rank 6 on the virtual screening list) and 4 (rank 4 on the virtual screening list) exhibit the desired receptor activation with EC 50 values of 7.2 and 3.6 µM, respectively (Figure 8 ). Both belong to the same chemotype containing an iminothiazolinone core and a benzoic acid moiety as a bioisosteric replacement of the fibrate group present in the query structures ( Figure 7) . Notably, compound 4 contains an additional carboxylic function, which could also be regarded as a fibrate replacement.
Summarizing, virtual screening of a large compound collection by the exit-vector approach led to a novel class of PPARα agonists with minimal experimental effort needed. This encouraging outcome stimulates additional prospective studies aiming at bioisosteric replacement of natural product scaffolds. Future development of the concept will include advanced shape descriptions of scaffolds and side chains [26] .
